The 7th ISCC

December 2-3, 2002
Keidanren Hall

December 2, 2002 (Mon)

13:00 - 13:10

Haruo Sugano (Cancer Chemotherapy Center, Tokyo)

Welcome and Introduction

I Drug Development based on Genome Science

Chairpersons: Robert H. Shoemaker (NCI-Frederick, Frederick)
Nagahiro Saijo (National Cancer Center Hosp., Tokyo)

13:10–13:50

David G. Covell (NCI-Frederick, Frederick)

Relating anticancer drug screening data to structural features of chemical libraries

13:50–14:20

Yoichi Furukawa (Univ. Tokyo, Tokyo)

Identification and characterization of novel molecular targets for cancer

chemotherapy using genome-wide cDNA microarray

14:20–14:50

Hiroyuki Aburatani (Univ. Tokyo, Tokyo)

Transcriptome analysis for cancer therapeutics

14:50–15:00

Discussion

15:00–15:20

Coffee Break

15:20–16:00

Ron van Schaik (Erasmus Medical Center, Rotterdam)

Pharmacogenetics

16:00–16:30

Yoshio Miki (Japanese Foundation for Cancer Research and Tokyo Medical Dental Univ., Tokyo)

Large-scale genomic studies in cancer patients for personalized chemotherapy

16:30–16:40

Discussion

II New Mechanism of Drug Resistance

Chairpersons: David G. Covell (NCI-Frederick, Frederick)
Ryuzo Ueda (Nagoya City Univ., Nagoya)

16:40–17:10

Yoshikazu Sugimoto (Cancer Chemotherapy Center, Tokyo)

Breast cancer resistance protein (BCRP): physiological substrates, reversing

agents and SNPs

17:10 - 17:40

Kazuto Nishio (National Cancer Center Research Institute, Tokyo)

Resistance mechanism of ZD1839

17:40–18:00

Discussion

18:00–19:00

Mixer

December 3, 2002 (Tue)

III New Anticancer Agents under Clinical Considerations

Chairpersons: Edward A. Sausville (NCI, Bethesda)
Masahiro Fukuoka (Kinki Univ, Osaka)

09:30–09:55

Saburo Sone (Tokushima Univ., Tokushima)

ZD6126 (tublin binding inhibitor, vascular targeting agent)

09:55–10:20

Nobuyuki Yamamoto (Shizuoka Cancer Center Hospital, Shizuoka)

TZT-1027

10:20–10:40

Coffee Break

10:40–11:05

Masanori Suzuki (Daiichi Pharmaceutical Co., Ltd., Tokyo)

Preliminary results of DE-310 (macromolecular carrier conjugated DX-8951) phase I studies

11:05–11:30

Jun Ohtsu (National Cancer Center Hospital, Tokyo)

Oxaliplatin

11:30–12:10

Manuel Hidalgo (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore)

mTOR inhibitor

12:10–12:20

Discussion

12:20–13:30

Lunch Break

IV Kinases as Targets

Chairpersons: Manuel Hidalgo (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore)
Yutaka Ariyoshi (Aichi Hosp., Nagoya)

13:30–13:55

Masakazu Toi (Tokyo Metropolitan Komagome Hospital, Tokyo)

Herceptin: Its current topics and future perspectives

13:55–14:20

Kiyoshi Yokokawa (Takeda Chemical Industries, Ltd., Tokyo)

TAK165

14:20–14:45

Kazuhiko Nakagawa (Kinki Univ., Osaka)

EGFR tyrosine kinase inhibitors: ZD1839 and ZD6474

14:45–15:25

Jaap Verweij (Rotterdam Cancer Institute, Rotterdam)

Glivec for GIST, a new paradigm for the treatment of solid tumors

15:25–15:35

Discussion

15:35–15:55

Coffee Break

V Target-based Drug Development

Chairpersons: Jaap Verweij (Rotterdam Cancer Institute, Rotterdam)
Takashi Tsuruo (Univ. Tokyo, Tokyo)

15:55–16:20

Naoya Fujita (Univ. Tokyo, Tokyo)

Akt/PKB pathway as a promising target for cancer chemotherapy

16:20–17:00

Robert H. Shoemaker (NCI-Frederick, Frederick)

Targeting the HIF-1 alpha signaling pathway for cancer therapy

17:00–17:40

Edward A. Sausville (NCI, Bethesda)

Novel DNA-damaging strategies

17:40–17:50

Discussion

17:50 - 18:00

Takashi Tsuruo (Univ. Tokyo, Tokyo)

Closing Remark

Page TOP